As the leading supplier of flexible high-density microarray products, NimbleGen enabled a new era of “High Definition Genomics.”
Venture Investors led the second and fourth rounds of financing, developing a strategy to simplify the capital structure in a way that appealed to all constituencies. We introduced the company to several members of their early management team. John Neis served on the Board of Directors until acquisition.
NimbleGen was acquired by Roche for $270 million.